BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia

Bookmark and Share
Published: 23 Jun 2020
Views: 521
Rating:
Save
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

Dr Josep Ribera speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He discusses BLIN-01 trial which looks at blinatumomab use during consolidation in adult patients with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia.

He outlines the trial design, results and toxicity profile.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.